Background: Plasmodium vivax malaria accounts for approximately 88% of malaria cases in Iran. There is limited in­formation on genetic diversity of P. vivax in the country and a need to develop and apply an effective vaccine against the dis­ease is necessary. Among many potential candidates, MSP -3β gene is promising target. This study was designed and car­ried out to determine the variation of this gene as genetic marker in population of malarious areas of Iran.Methods: Blood sample of 85 P. vivax isolates from four southern and east-southern provinces of the country assessed for poly­morphism of PvMSP-3β gene by PCR/RFLP method. Results:  Based on the size of PCR product of the ge...
Reliable molecular markers are essential for a better understanding of the molecular epidemiology of...
Block II of Plasmodium vivax merozoite surface protein 3α (PvMSP3α) is conserved and has been propos...
Background: Vivax malaria is more prevalent in the malarious areas of Iran, which makes vaccine rese...
Background: The worldwide distribution of P. vivax has expanded significantly and the number of repo...
Approximately 90 million people are suffered from vivax malaria annually. This disease imposes a hea...
Genetic diversity and population structure of Plasmodium vivax parasites are valuable to the predict...
Genetic diversity and population structure of Plasmodium vivax parasites are valuable to the predict...
Background & objectives: Malaria, an ancient human infectious disease caused by five species of ...
Carboxy-terminal 42 kDa region of Plasmodium vivax merozoite surface protein-1 is considered as an i...
Background: Plasmodium vivax, although causing a less serious disease than Plasmodium falciparum, is...
Background: Genetic diversity of Plasmodium falciparum-the main causative agent of malaria- provides...
Background: Plasmodium vivax is responsible for approximately 80 million malaria cases in the world....
Abstract. Allelic diversity at the Plasmodium vivax merozoite surface protein-3a (PvMsp-3a) locus wa...
BACKGROUND: Plasmodium vivax malaria accounts for approximately 60% of malaria cases in Kolkata, Ind...
Background: Plasmodium vivax is the second most prevalent human malaria parasite in Bangladesh; howe...
Reliable molecular markers are essential for a better understanding of the molecular epidemiology of...
Block II of Plasmodium vivax merozoite surface protein 3α (PvMSP3α) is conserved and has been propos...
Background: Vivax malaria is more prevalent in the malarious areas of Iran, which makes vaccine rese...
Background: The worldwide distribution of P. vivax has expanded significantly and the number of repo...
Approximately 90 million people are suffered from vivax malaria annually. This disease imposes a hea...
Genetic diversity and population structure of Plasmodium vivax parasites are valuable to the predict...
Genetic diversity and population structure of Plasmodium vivax parasites are valuable to the predict...
Background & objectives: Malaria, an ancient human infectious disease caused by five species of ...
Carboxy-terminal 42 kDa region of Plasmodium vivax merozoite surface protein-1 is considered as an i...
Background: Plasmodium vivax, although causing a less serious disease than Plasmodium falciparum, is...
Background: Genetic diversity of Plasmodium falciparum-the main causative agent of malaria- provides...
Background: Plasmodium vivax is responsible for approximately 80 million malaria cases in the world....
Abstract. Allelic diversity at the Plasmodium vivax merozoite surface protein-3a (PvMsp-3a) locus wa...
BACKGROUND: Plasmodium vivax malaria accounts for approximately 60% of malaria cases in Kolkata, Ind...
Background: Plasmodium vivax is the second most prevalent human malaria parasite in Bangladesh; howe...
Reliable molecular markers are essential for a better understanding of the molecular epidemiology of...
Block II of Plasmodium vivax merozoite surface protein 3α (PvMSP3α) is conserved and has been propos...
Background: Vivax malaria is more prevalent in the malarious areas of Iran, which makes vaccine rese...